BiotechTube

Risdiplam

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscular Atrophy, Spinal

Conditions

Muscular Atrophy, Spinal

Trial Timeline

May 16, 2019 → Jan 2, 2020

NCT ID
NCT03920865

About Risdiplam

Risdiplam is a phase 1 stage product being developed by Roche for Muscular Atrophy, Spinal. The current trial status is completed. This product is registered under clinical trial identifier NCT03920865. Target conditions include Muscular Atrophy, Spinal.

What happened to similar drugs?

20 of 20 similar drugs in Muscular Atrophy, Spinal were approved

Approved (20) Terminated (3) Active (0)
✅GoserelinAstraZenecaApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved
✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved
✅Sugammadex + RocuroniumMerckApproved
✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved
✅neostigmine/glycopyrrolate + sugammadexMerckApproved
✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (7)

NCT IDPhaseStatus
NCT05861999ApprovedRecruiting
NCT05861986ApprovedRecruiting
NCT05808764Phase 2Recruiting
NCT03779334Phase 2Active
NCT03920865Phase 1Completed
NCT03032172Phase 2Completed
NCT02913482Phase 2Completed

Competing Products

20 competing products in Muscular Atrophy, Spinal

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
29
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
29
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
29
Tadalafil + PlaceboEli LillyPhase 3
32
DS-5141bDaiichi SankyoPhase 2
39
DS-5141bDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
32
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
35
LY2495655 + PlaceboEli LillyPhase 2
35
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
42
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
35
NS-065/NCNP-01Nippon ShinyakuPhase 2
35
Viltolarsen + PlaceboNippon ShinyakuPhase 3
40
ViltolarsenNippon ShinyakuPhase 2
35
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
39
NS-065/NCNP-01Nippon ShinyakuPhase 1
29
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
39
NS-089/NCNP-02Nippon ShinyakuPhase 2
42